ACET ADICET BIO INC US FDA Inspections 8-K Filing 2024 - FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma Adicet Bio, Inc. received FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma.Get access to all SEC 8-K filings of the ADICET BIO INC